Effectiveness and Cost-effectiveness of an Integrated Psychological Internet Intervention (MindWellness) in Chinese COPD Patients: Study Protocol of a Randomized Controlled Trial

Sponsor
Peking Union Medical College (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06026709
Collaborator
(none)
1,200
2
9

Study Details

Study Description

Brief Summary

Background Mental health problems in chronic obstructive pulmonary disease (COPD) patients are prominent and neglected. Web-based self-help therapies may effectively reduce mental health problems, but their effectiveness has not been evaluated in Chinese COPD patients. We developed an integrated Internet-based psychological intervention (MindWellness). This study aims to evaluate the effectiveness and cost-effectiveness of MindWellness in enhancing the mental wellbeing of COPD patients.

Methods This study is a multicenter, two-arm, randomized controlled trial (RCT) with a parallel-group design to enroll at least 420 COPD patients over 35 years. Participants will be assigned to receive either usual care group or the usual care + MindWellness group. Assessments will take place at baseline (T0), 4 weeks (T1), 8 weeks (T2), and 16 weeks (T3) after baseline, and participants will be asked to complete questionnaires and take physical measurements. The primary outcome measure will assess mental well-being using the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS). Secondary outcome measures will assess mental health, physical health, COPD symptoms, health risk behaviors, socio-economic indicators, and healthcare utilization and expenditure. Analyses will utilize an intention-to-treat analysis.

Discussion This study is the first RCT to examine the value of MindWellness, the internet-based psychological intervention for COPD patients. If this low-cost intervention is effective, it could be rapidly scaled up for providing mental health care of COPD patients in China.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: MindWellness
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Effectiveness and Cost-effectiveness of an Integrated Psychological Internet Intervention (MindWellness) in Chinese COPD Patients: Study Protocol of a Randomized Controlled Trial
Anticipated Study Start Date :
Sep 15, 2023
Anticipated Primary Completion Date :
Apr 15, 2024
Anticipated Study Completion Date :
Jun 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: usual care + MindWellness group

Behavioral: MindWellness
The online intervention "MindWellness" integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program.

No Intervention: usual care

Outcome Measures

Primary Outcome Measures

  1. the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS) [at baseline (T0), 4 weeks (T1), 8 weeks (T2), and 16 weeks (T3) after baseline]

    Patients'mental wellbeing

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 35 years or older;

  2. Post-bronchodilator FEV1/FVC ≤70% or confirmed COPD patients;

  3. Literate and able to type;

  4. Have a smartphone;

  5. Be proficient in using the WeChat applet;

  6. Willingness to self-help iCBT sessions for 8 weeks, 10-20 minutes of practice per session, roughly 1 hour per week, time and place flexible;

  7. Receive three follow-up visits within four months (2 offline, 1 online) and complete a physical exam and online questionnaire; and

  8. Willingness to provide the hospital with their usual cell phone number.

Exclusion Criteria:
  1. Patients with a physician diagnosis of asthma or asthma-COPD overlap syndrome;

  2. Patients hospitalized for COPD within the previous one year;

  3. Having severe cognitive dysfunction and being unable to communicate;

  4. Severely ill with less than 12-month life expectancy.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking Union Medical College

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Simiao Chen, professor, Peking Union Medical College
ClinicalTrials.gov Identifier:
NCT06026709
Other Study ID Numbers:
  • CAMS&PUMC-IEC-2023-018
First Posted:
Sep 7, 2023
Last Update Posted:
Sep 7, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 7, 2023